Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold

August 1, 2022 6:50 AM EDT
Get Alerts CORT Hot Sheet
Price: $25.37 --0%

Rating Summary:
    9 Buy, 6 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 4 | Down: 11 | New: 14
Join SI Premium – FREE

Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $28.66 yesterday.

You May Also Be Interested In

Related Categories